HIGH POINT —VTV Therapeutics (vTv), ((Nasdaq: VTVT), a clinical-stage pharmaceutical company focused on the discovery and development of human therapeutics to fill unmet medical needs has raised $1.5 million in equity, according to a regulatory filing.
The round is aimed at $10 million.
The company says its mission is to advance clinical drug candidates discovered with innovative technology into safe and effective medicines.
VTV has a pipeline of small molecule clinical and pre-clinical drug candidates for the treatment of a wide range of human diseases including Alzheimer’s disease, Type II diabetes and inflammation, according to its web site.
The company has built its product candidate portfolio through internal discovery and is advancing its product candidates through in-house research and development efforts.
VTV developed a proprietary drug discovery engine called TTP Translational Technology that it used to discover and develop novel therapeutics for major diseases. Almost all of the drug candidates in our pipeline were discovered using this technology.
According to the company, “TTP Translational Technology is a highly automated and fully integrated drug discovery process, which translates genomic and proteomic data into promising small molecule therapeutics in a high throughput fashion, bypassing many of the traditional bottlenecks in drug discovery.”
The company was notified by Nasdaq in 2018 that it no longer satisfied the minimum market value of listed securities requirement for the Nasdaq Global Market. In response, vTv transfered the listing of its Class A Common Stock to The Nasdaq Capital Market.
VTV Therapeutics reports lower net loss after decreasing expenses
Disappointing Alzheimer’s drug trial results send VTV Therapeutics shares plunging
